Lifespan vs. Healthspan: How Geroscience Categorizes Aging Pathways
Biogerontologists distinguish between chronological lifespan (total years lived) and healthspan (years lived free from frailty, sarcopenia, metabolic dysfunction, and cognitive decline). Rather than treating aging as a single process, peer-reviewed geroscience maps compounds against the recognized Hallmarks of Aging:
- Telomere Attrition & Epigenetic Drift: Progressive shortening of TTAGGG chromosomal caps during somatic cell division until cells reach the Hayflick limit and enter replicative senescence.
- Mitochondrial Dysfunction & Deregulated Nutrient Sensing: Declining intracellular NAD+ pools, reduced sirtuin activity, and blunted AMPK signaling.
- Extracellular Matrix Crosslinking & Loss of Proteostasis: Fragmentation of dermal and vascular Type I/III collagen and elastin.
- Immunosenescence & "Inflammaging": Involution of the thymus gland, reduced naive T-cell output, and chronic low-grade inflammatory cytokine elevation.
Comparing Longevity & Healthy-Aging Research Compounds
| Compound | Hallmark of Aging Targeted | Primary Molecular Mechanism | Published Evidence Base | U.S. Regulatory Status (Apr 2026) |
|---|---|---|---|---|
| Epithalon | Telomere attrition & circadian decline | Telomerase activation in cell models; pineal melatonin rhythm support | In vitro human cell studies & animal aging studies | Unapproved; nominated for Category 2 but withdrawn |
| GHK-Cu | Extracellular matrix & tissue remodeling | Stimulates collagen & elastin synthesis; supports antioxidant & anti-inflammatory pathways | Human topical facial studies & wound-repair research | Topical cosmetic allowed; injectable nominated for Category 2 but withdrawn |
| NAD+ & MOTS-c | Mitochondrial bioenergetics & nutrient sensing | Cellular redox & sirtuin cofactor (NAD+); mitochondrial AMPK signaling (MOTS-c) | Animal metabolic models & human NAD+ precursor studies | NAD+ injectable unapproved; MOTS-c nominated for Category 2 but withdrawn |
| Thymosin Alpha-1 | Thymic involution & immunosenescence | T-cell maturation & immune-response modulation | International clinical approvals & human immune studies | Unapproved in U.S.; nominated for Category 2 but withdrawn |
| Sermorelin / Ipamorelin | Endocrine somatopause (GH/IGF-1 decline) | Pulsatile pituitary somatotroph GH release; lean mass & bone turnover | Human clinical studies in age-related GH decline | Sermorelin: discontinued Rx / 503A path; Ipamorelin acetate: Cat. 2 |
1. Epithalon: Telomerase Expression & Pineal Bioregulation
Epithalon (Ala-Glu-Asp-Gly) is a synthetic tetrapeptide modeled on a natural pineal peptide preparation. Research describes Epithalon’s geroprotective effects across multiple aging pathways (PubMed).
Preclinical and aging reviews (PMC3833489) have also examined Epithalon's effects on nocturnal melatonin secretion, antioxidant defenses, and lifespan parameters in animal models. However, large independent multicenter clinical trials establishing human longevity outcomes have not been completed.
2. GHK-Cu: Dermal Remodeling & Cellular Repair
GHK-Cu is a naturally occurring copper-binding tripeptide whose concentration in human plasma declines with age. Research published in dermatological and tissue-repair literature (PMID 22452730) shows that GHK-Cu stimulates collagen and elastin synthesis, supports wound healing and tissue remodeling, and modulates gene expression related to antioxidant defense and tissue regeneration.
3. NAD+ and MOTS-c: Mitochondrial Bioenergetics
Age-related mitochondrial decline is associated with falling cellular NAD+ concentrations (PMC6342515) and reduced metabolic flexibility. While NAD+ serves as an essential coenzyme for mitochondrial energy production, DNA repair, and sirtuin activity, the mitochondrial-encoded peptide MOTS-c activates the AMPK pathway to support glucose metabolism and cellular resilience under metabolic stress.
4. Growth-Hormone Secretagogues & Age-Related Endocrine Decline
In clinical endocrinology, GHRH analogs (Sermorelin, CJC-1295) and ghrelin mimetics (Ipamorelin) have been studied for how they stimulate pulsatile pituitary growth hormone signaling as endogenous GH and IGF-1 levels decline with age—a process associated with changes in lean muscle mass, adipose distribution, bone turnover, and skin thickness (PMID 9849822).
Because aging involves distinct cellular, structural, and hormonal mechanisms, researchers distinguish between compounds studied for endocrine signaling and those investigated for dermal matrix support, mitochondrial bioenergetics, or thymic immune regulation. Long-term human longevity outcomes remain unestablished across these investigational pathways, and growth-hormone-elevating compounds carry specific cautions regarding glucose tolerance, fluid retention, and potential stimulation of existing malignancies.
On FDA's Bulk Drug Substances page current as of April 22, 2026, Epithalon, GHK-Cu injectable, MOTS-c, CJC-1295, and Thymosin Alpha-1 are listed as nominated for 503A Category 2 but withdrawn, while Ipamorelin acetate remains listed in Category 2. None of these compounds are FDA-approved for anti-aging or longevity. Human safety during pregnancy or breastfeeding remains unestablished for these investigational peptides. Furthermore, any compound that elevates growth hormone/IGF-1 or stimulates telomerase or angiogenesis requires strict caution in individuals with active or prior malignancy.